A primer on concentrated insulins: what an internist should know

References

• Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28:1240–1244. doi:10.2337/diacare.28.5.1240.
   PubMed Web of Science ®Google Scholar
• Harmel AP, Mathur R. Similar A1C outcomes in type 1 diabetic patients undergoing intensive diabetes management with preprandial rapid-acting insulin and either CSII or glargine. Diabetes Care. 2004;27(1):272–273.
   Google Scholar
• DeFronzo RA, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194. doi:10.2337/diacare.14.3.173.
   PubMed Web of Science ®Google Scholar
• Ballani P, Tran MT, Navar MD, et al. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. Diabetes Care. 2006;29:2504–2505. doi:10.2337/dc06-1478.
   PubMed Web of Science ®Google Scholar
• Garg R, Johnston V, McNally PG, et al. U-500 insulin: why, when and how to use in clinical practice. Diabetes Metab Res Rev. 2007;23:265–268. doi:10.1002/(ISSN)1520-7560.
   PubMed Web of Science ®Google Scholar
• Galloway JA, Spradlin CT, Nelson RL, et al. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care. 1981;4:366–376. doi:10.2337/diacare.4.3.366.
   PubMed Web of Science ®Google Scholar
• Binder C. Absorption of injected insulin. A clinical-pharmacological study. Acta Pharmacol Toxicol (Copenh). 1969;27(S2):1–83.
   PubMedGoogle Scholar
• Davidson MB, Navar MD, Echeverry D, et al. U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care. 2010;33:281–283. doi:10.2337/dc09-1490.
   PubMed Web of Science ®Google Scholar
• Mari A, Rosenstock J, Ma X, et al. Optimized Human Regular U-500 Insulin Treatment Improves β-CELL Function In Severely Insulin-Resistant Patients With Long-Standing Type 2 Diabetes and High Insulin Requirements. Endocr Pract. 2015;21:1344–1352. doi:10.4158/EP15898.OR.
   PubMed Web of Science ®Google Scholar
• Ziesmer AE, Kelly K, Guerra P, et al. U500 regular insulin use in insulin-resistant type 2 diabetic veteran patients. Endocr Pract. 2012;18:34–38. doi:10.4158/EP11043.OR.
   PubMed Web of Science ®Google Scholar
• Boldo A, Comi RJ. Clinical experience with U500 insulin: risks and benefits. Endocr Pract. 2012;18:56–61. doi:10.4158/EP11163.OR.
   PubMed Web of Science ®Google Scholar
• Granata JA, Nawarskas AD, Resch ND, et al. Evaluating the effect of u-500 insulin therapy on glycemic control in veterans with type 2 diabetes. Clin Diabetes. 2015;33:14–19. doi:10.2337/diaclin.33.1.14.
   PubMedGoogle Scholar
• Reutrakul S, Wroblewski K, Brown RL. Clinical use of U-500 regular insulin: review and meta-analysis. J Diabetes Sci Technol. 2012;6:412–420. doi:10.1177/193229681200600229.
   PubMedGoogle Scholar
• Dailey AM, Williams S, Taneja D, et al. Clinical efficacy and patient satisfaction with U-500 insulin use. Diabetes Res Clin Pract. 2010;88:259–264. doi:10.1016/j.diabres.2010.02.012.
   PubMed Web of Science ®Google Scholar
• Wafa WS, Khan MI. Use of U-500 regular insulin in type 2 diabetes. Diabetes Care. 2006;29:2175–2176. doi:10.2337/dc06-1148.
   PubMed Web of Science ®Google Scholar
• Lane WS, Cochran E, Jackson J, et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009;15:71–79. doi:10.4158/EP.15.1.71.
   PubMed Web of Science ®Google Scholar
• As U-500 Insulin Safety Concerns Mount, It’s Time To Rethink Safe Use Of Strengths Above U-100. 2013. Available from: http://www.ismp.org/newsletters/acutecare/showarticle.aspx?id=62
   Google Scholar
• Lane WS, Weinrib S, Rappaport J, et al. The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes. Endocr Pract. 2013;19:196–201. doi:10.4158/EP12226.OR.
   PubMed Web of Science ®Google Scholar
• Bulchandani DG, Konrady T, Hamburg MS. Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes. Endocr Pract. 2007;13:721–725. doi:10.4158/EP.13.7.721.
   PubMedGoogle Scholar
• Knee TS, Treyce S, Seidensticker DF, et al. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series. Endocr Pract. 2003;9(3):181–186.
   PubMedGoogle Scholar
• Reutrakul S, Brown RL, Koh C-K, et al. Use of U-500 regular insulin via continuous subcutaneous insulin infusion: clinical practice experience. J Diabetes Sci Technol. 2011;5:1025–1026. doi:10.1177/193229681100500429.
   PubMedGoogle Scholar
• Hatipoglu B, Soni S, Espinosa V. Glycemic control with continuous subcutaneous insulin infusion with use of U-500 insulin in a pregnant patient. Endocr Pract. 2006;12:542–544. doi:10.4158/EP.12.5.542.
   PubMedGoogle Scholar
• Zuckerwise LC, Werner EF, Pettker CM, et al. Pregestational diabetes with extreme insulin resistance: use of U-500 insulin in pregnancy. Obstet Gynecol. 2012;120:439–442. doi:10.1097/AOG.0b013e31824fd27d.
   PubMed Web of Science ®Google Scholar
• Okeigwe I, Yeaton-Massey A, Kim S, et al. U-500R and aspart insulin for the treatment of severe insulin resistance in pregnancy associated with pregestational diabetes. J Perinatol. 2013;33:235–238. doi:10.1038/jp.2012.70.
   PubMed Web of Science ®Google Scholar
• Mendez-Figueroa H, Maggio L, Dahlke JD, et al. Treatment of severe insulin resistance in pregnancy with 500 units per milliliter of concentrated insulin. Obstet Gynecol. 2013;122:99–104. doi:10.1097/AOG.0b013e3182978a11.
   PubMed Web of Science ®Google Scholar
• Lane WS, Weinrib S, Rappaport J, et al. A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance. Endocr Pract. 2010;16:778–784. doi:10.4158/EP10014.OR.
   PubMed Web of Science ®Google Scholar
• Tripathy PR, Lansang MC. U-500 regular insulin use in hospitalized patients. Endocr Pract. 2015;21:54–58. doi:10.4158/EP14151.OR.
   PubMed Web of Science ®Google Scholar
• Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 Units mL−1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units mL−1. Diabetes Care. 2015;38(4):637–643.
   PubMed Web of Science ®Google Scholar
• Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with diabetes. Diabetes Obes Metab. 2015;17:254–260. doi:10.1111/dom.2015.17.issue-3.
   PubMed Web of Science ®Google Scholar
• Becker RH, Nowotny I, Teichert L, et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab. 2015;17:261–267. doi:10.1111/dom.2015.17.issue-3.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37:2755–2762. doi:10.2337/dc14-0991.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Yki-Järvinen H, Bolli GB, et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab. 2015;17:835–842. doi:10.1111/dom.2015.17.issue-9.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37:3235–3243. doi:10.2337/dc14-0990.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17:386–394. doi:10.1111/dom.2015.17.issue-4.
   PubMed Web of Science ®Google Scholar
• Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17:859–867. doi:10.1111/dom.2015.17.issue-9.
   PubMed Web of Science ®Google Scholar
• Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 Units/mL versus glargine 100 Units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38:2217–2225. doi:10.2337/dc15-0249.
   PubMed Web of Science ®Google Scholar
• Bode BW, Chaykin L, Sussman A, et al. Efficacy and safety of insulin degludec 200 U/mL and insulin degludec 100 U/mL in patients with type 2 diabetes (begin: compare). Endocr Pract. 2014;20:785–791. doi:10.4158/EP13411.OR.
   PubMed Web of Science ®Google Scholar
• Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig. 2013;33:515–521. doi:10.1007/s40261-013-0096-7.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Gross JL, Ono Y, et al. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab. 2014;16:922–930. doi:10.1111/dom.2014.16.issue-10.
   PubMed Web of Science ®Google Scholar
• Bode BW, Buse JB, Fisher M, et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN((R)) basal-bolus type 1): 2-year results of a randomized clinical trial. Diabet Med. 2013;30(11):1293–1297.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98:1154–1162. doi:10.1210/jc.2012-3249.
   PubMed Web of Science ®Google Scholar
• Koehler G, Heller S, Korsatko S, et al. Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study. Diabetologia. 2014;57:40–49. doi:10.1007/s00125-013-3056-0.
   PubMed Web of Science ®Google Scholar
• Garber AJ, King AB, Prato SD, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN basal-bolus type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. The Lancet. 2012;379:1498–1507. doi:10.1016/S0140-6736(12)60205-0.
   PubMed Web of Science ®Google Scholar
• Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36(4):858–864.
   PubMed Web of Science ®Google Scholar
• Zinman B, DeVries JH, Bode B, et al. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes Endocrinol. 2013;1:123–131. doi:10.1016/S2213-8587(13)70013-5.
   PubMed Web of Science ®Google Scholar
• Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34:669–674. doi:10.2337/dc10-1905.
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Bode B, Courreges J-P, et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care. 2012;35:2174–2181. doi:10.2337/dc11-2503.
   PubMed Web of Science ®Google Scholar
• Fulcher GR, Christiansen JS, Bantwal G, et al. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care. 2014;37:2084–2090. doi:10.2337/dc13-2908.
   PubMed Web of Science ®Google Scholar
• Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885–893.
   PubMed Web of Science ®Google Scholar
• Buse JB, Vilsbøll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37:2926–2933. doi:10.2337/dc14-0785.
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Bøttcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944–950.
   PubMed Web of Science ®Google Scholar
• Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859–864. doi:10.1111/dom.2012.14.issue-9.
   PubMed Web of Science ®Google Scholar
• Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36(9):2536–2542.
   PubMed Web of Science ®Google Scholar
• de la Peña A, Seger M, Soon D, et al. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL. Clin Pharm Drug Dev. 2016;5(1):69–75.
   PubMed Web of Science ®Google Scholar
• Morrow L, Hompesch M, Canney L, et al. Biphasic pharmacokinetic and pharmacodynamic profiles associated with concentrated insulin BIOD-531 show rapid onset and basal duration of action. In Diabetologia. New York (NY): Springer; 2014. Vol. 57, p. S383–S383.
   Google Scholar
• Greene JA, Riggs KR. Why is there no generic insulin? Historical origins of a modern problem. N Engl J Med. 2015;372:1171–1175. doi:10.1056/NEJMms1411398.
   PubMed Web of Science ®Google Scholar
• Hirsch IB. Diabetes care entering 2015: ineffective ranting. Diabetes Technol Ther. 2015;17:69–71. doi:10.1089/dia.2015.0005.
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Ross JS, Van Houten HK, et al. Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010. Jama. 2014;311:2331. doi:10.1001/jama.2014.6316.
   PubMed Web of Science ®Google Scholar
• Tylee T, Hirsch IB. Costs associated with using different insulin preparations. Jama. 2015;314:665. doi:10.1001/jama.2015.7032.
   PubMed Web of Science ®Google Scholar
• Peters AL, Pollom RD, Zielonka JS, et al. Biosimiliars and New Insulin Versions. Endocr Pract. 2015;21:1387–1394. doi:10.4158/EP14595.RA.
   PubMedGoogle Scholar